WO2023133131 - METHODS FOR CANCER DETECTION AND MONITORING
National phase entry:
Publication Number
WO/2023/133131
Publication Date
13.07.2023
International Application No.
PCT/US2023/010101
International Filing Date
04.01.2023
Title **
[English]
METHODS FOR CANCER DETECTION AND MONITORING
[French]
PROCÉDÉS DE DÉTECTION ET DE SUIVI DU CANCER
Applicants **
NATERA, INC.
Inventors
KALASHNIKOVA, Ekaterina
WU, Hsin-Ta
MEHTA, Samay
SALARI, Raheleh
ZIMMERMANN, Bernhard
BILLINGS, Paul
ALESHIN, Alexey
Priority Data
63/296,394
04.01.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3421 | |
| EPO | Filing, Examination, Granting | 15603 | |
| Japan | Filing, Examination, Granting | 2315 | |
| South Korea | Filing, Examination, Granting | 2366 | |
| USA | Filing, Examination, Granting | 5640 |
Total:
29,345
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention provides methods for preparing a preparation of amplified DNA derived from a biological sample of a patient who has been diagnosed with cancer useful for determining relapse or metastasis of cancer, comprising (a) sequencing DNA isolated from hematopoiesis cells in a blood or bone marrow sample of the patient or a fraction thereof to determine the presence or absence of one or more clonal hematopoiesis of indeterminate potential (CHIP) mutations; (b) sequencing (i) DNA isolated from a tumor biopsy sample of the patient or (ii) cell-free DNA isolated from the blood or bone marrow sample or a fraction thereof, to identify a plurality of patient-specific somatic mutations associated with the cancer; (c) preparing a preparation of amplified DNA by performing targeted multiplex amplification on cell-free DNA isolated from a longitudinally collected biological sample of the patient or a fraction thereof to amply a plurality of target loci to obtain amplified DNA, wherein each of the target loci spans a patient-specific somatic mutation identified in step (b) and does not span any CHIP mutation identified in step (a), wherein the biological sample is a blood, urine, or bone marrow sample; and (d) analyzing the preparation of amplified DNA by sequencing the amplified DNA to determine the presence or absence of the patient-specific somatic mutations, wherein the presence of two or more patient-specific somatic mutations associated with the cancer and the presence of one or more CHIP mutations are indicative of relapse or metastasis of the cancer.[French]
chacun des loci cibles couvre une mutation somatique spécifique du patient identifiée à l'étape (b) et ne couvre aucune mutation CHIP identifiée à l'étape (a), l'échantillon biologique étant un échantillon sanguin, urinaire ou de moelle osseuse ; et (d) analyse de la préparation d'ADN amplifié par séquençage de l'ADN amplifié pour déterminer la présence ou l'absence des mutations somatiques spécifiques du patient, la présence d'au moins deux mutations somatiques spécifiques du patient associées au cancer et la présence d'une ou plusieurs mutations CHIP indiquant une rechute ou une métastase du cancer.